Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
EphB6-null mutation results in compromised T cell function
Hongyu Luo, … , Johanne Tremblay, Jiangping Wu
Hongyu Luo, … , Johanne Tremblay, Jiangping Wu
Published December 15, 2004
Citation Information: J Clin Invest. 2004;114(12):1762-1773. https://doi.org/10.1172/JCI21846.
View: Text | PDF
Article Immunology

EphB6-null mutation results in compromised T cell function

  • Text
  • PDF
Abstract

So far, there is very limited knowledge about the role of Eph kinases, the largest family of receptor tyrosine kinases, in the immune system. Here, using EphB6–/– mice, we demonstrated that in vitro and in vivo T cell responses such as lymphokine secretion, proliferation, and the development of delayed-type skin hypersensitivity and experimental autoimmune encephalitis in EphB6–/– mice were compromised. On the other hand, humoral immune responses, such as serum levels of different Ig isotypes and IgG response to tetanus toxoid, were normal in these mice. Mechanistically, we showed that EphB6 migrated to the aggregated TCRs and rafts after TCR activation. Further downstream, in the absence of EphB6, ZAP-70 activation, LAT phosphorylation, the association of PLCγ1 with SLP-76, and p44/42 MAPK activation were diminished. Thus, we have shown that EphB6 is pivotal in T cell function.

Authors

Hongyu Luo, Guang Yu, Johanne Tremblay, Jiangping Wu

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Intracellular signaling events downstream of EphB6. Bar graphs show the ...
Intracellular signaling events downstream of EphB6. Bar graphs show the density ratios of phosphorylated molecules versus total protein (as loading controls) of the molecule. (A) EphB6 was required for optimal LAT phosphorylation. EphB6+/+ or EphB6–/– thymocytes were cross-linked with anti-CD3 and anti-CD4 mAbs for 0–5 minutes, as indicated. The cell lysates were immunoblotted (Blot) with Ab against phosphorylated LAT (p-LAT) first (upper panel); the membrane was stripped and reblotted with Ab against LAT (lower panel). (B) EphB6 was required for optimal ZAP-70 phosphorylation. EphB6+/+ or EphB6–/– thymocytes were cross-linked with anti-CD3 and anti-CD4 mAbs for 0 minutes (resting) or 1 minute (activated). The cell lysates were immunoblotted (Blot) with Ab against phosphorylated ZAP-70 (p-ZAP-70) first (upper panel); the membrane was stripped and reblotted with Ab against ZAP-70 (lower panel). (C) EphB6 was not necessary for ZAP-70 membrane translocation. EphB6+/+ or EphB6–/– thymocytes were cross-linked with anti-CD3 and anti-CD4 for 0 minutes (resting) or 20 minutes (activated). The whole-cell lysates, cytosolic protein, and membrane protein, as indicated, were immunoblotted with Ab against ZAP-70. (D) EphB6 augmented binding of SLP-76 with PLCγ1 after TCR activation. EphB6+/+ or EphB6–/– thymocytes were cross-linked with anti-CD3 and anti-CD4 mAbs for 2 minutes. The lysates were immunoprecipitated (IP) with anti-PLCγ1 and blotted with anti–SLP-76 (upper panel). The same membrane was stripped and blotted again with anti-PLCγ1 (lower panel). (E) EphB6 was required for optimal Erk1/2 activation. EphB6+/+ or EphB6–/– thymocytes were cross-linked with anti-CD3 and anti-CD4 mAbs for 0–5 minutes, as indicated. The cell lysates were immunoblotted with Ab against phosphorylated Erk1/2 first (p-Erk1/2, upper panel); the same membrane was stripped and reblotted with Ab against Erk1/2 (lower panel).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts